
Incyte reported positive 54-week data for povorcitinib in hidradenitis suppurativa at the 2026 AAD Annual Meeting
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting Incyte announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor,…












